LeadIQ logo
Learn more at LeadIQ.com

Insights

Innovative Technology TumorGen's proprietary platform for capturing circulating metastatic cancer cell clusters presents a unique and targeted therapeutic approach, offering opportunities to collaborate with pharmaceutical companies seeking novel cancer metastasis targets.

Rapid Growth Potential With recent funding of $390K and revenue estimates between 1 million and 10 million dollars, there is significant growth potential for strategic partnerships and additional investment to expand operations and research capabilities.

Market Differentiation Operating in the competitive biotech space alongside firms like Guardant Health and Foundation Medicine, TumorGen's distinct focus on metastasis detection can position it as a specialist in precision oncology solutions.

Technology Stack Utilizing modern cloud and web technologies like Google Cloud CDN and Webpack indicates a scalable and agile tech infrastructure, which can be appealing for partners interested in digital health solutions and data integration.

Partnership Opportunities Given its focus on unmet needs in cancer detection and treatment, TumorGen offers avenues for collaborations with pharma and biotech firms looking to expand their drug discovery and diagnostic portfolios in oncology.

TumorGen, Inc. Tech Stack

TumorGen, Inc. uses 8 technology products and services including Google Cloud CDN, Open Graph, Webpack, and more. Explore TumorGen, Inc.'s tech stack below.

  • Google Cloud CDN
    Content Delivery Network
  • Open Graph
    Content Management System
  • Webpack
    Development
  • Wix eCommerce
    E-commerce
  • JSON-LD
    Javascript Frameworks
  • Lodash
    Javascript Libraries
  • Bootstrap
    UI Frameworks
  • YouTube
    Video Players

Media & News

TumorGen, Inc.'s Email Address Formats

TumorGen, Inc. uses at least 2 format(s):
TumorGen, Inc. Email FormatsExamplePercentage
FirstL@tumorgenmdx.comJohnD@tumorgenmdx.com
67%
FLast@tumorgenmdx.comJDoe@tumorgenmdx.com
33%
FLast@tumorgen.netJDoe@tumorgen.net
100%

Frequently Asked Questions

Where is TumorGen, Inc.'s headquarters located?

Minus sign iconPlus sign iconTumorGen, Inc.'s main headquarters is located at 6185 Cornerstone Court East, Suite #101 San Diego, CA 92121-4726, US. The company has employees across 1 continents, including North America.

What is TumorGen, Inc.'s official website and social media links?

Minus sign iconPlus sign iconTumorGen, Inc.'s official website is tumorgen.net and has social profiles on LinkedInCrunchbase.

What is TumorGen, Inc.'s SIC code NAICS code?

Minus sign iconPlus sign iconTumorGen, Inc.'s SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does TumorGen, Inc. have currently?

Minus sign iconPlus sign iconAs of October 2025, TumorGen, Inc. has approximately 5 employees across 1 continents, including North America. Key team members include Coo: S. R.. Explore TumorGen, Inc.'s employee directory with LeadIQ.

What industry does TumorGen, Inc. belong to?

Minus sign iconPlus sign iconTumorGen, Inc. operates in the Biotechnology Research industry.

What technology does TumorGen, Inc. use?

Minus sign iconPlus sign iconTumorGen, Inc.'s tech stack includes Google Cloud CDNOpen GraphWebpackWix eCommerceJSON-LDLodashBootstrapYouTube.

What is TumorGen, Inc.'s email format?

Minus sign iconPlus sign iconTumorGen, Inc.'s email format typically follows the pattern of FirstL@tumorgenmdx.com. Find more TumorGen, Inc. email formats with LeadIQ.

How much funding has TumorGen, Inc. raised to date?

Minus sign iconPlus sign icon As of October 2025, TumorGen, Inc. has raised $390K in funding. The last funding round occurred on Aug 26, 2021 for $390K.

When was TumorGen, Inc. founded?

Minus sign iconPlus sign iconTumorGen, Inc. was founded in 2017.

TumorGen, Inc.

Biotechnology ResearchUnited States2-10 Employees

TumorGen is developing a novel drug discovery platform to identify unseen therapeutic targets associated with cancer metastasis.  Our patented technology is used to capture circulating metastatic cancer cell clusters (MCCCs).  The MCCCs have been shown to be the primary vector for disseminating distant metastases in most solid tumor cancers.  Our innovative platform can open an entirely new therapeutic target space for biopharma developing drugs directly impacting the pathways of cancer metastasis.

Section iconCompany Overview

Headquarters
6185 Cornerstone Court East, Suite #101 San Diego, CA 92121-4726, US
Website
tumorgen.net
SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2017
Employees
2-10

Section iconMedia & News

Section iconFunding & Financials

  • $390K

    TumorGen, Inc. has raised a total of $390K of funding over 1 rounds. Their latest funding round was raised on Aug 26, 2021 in the amount of $390K.

  • $1M$10M

    TumorGen, Inc.'s revenue is estimated to be in the range of $1M$10M

Section iconFunding & Financials

  • $390K

    TumorGen, Inc. has raised a total of $390K of funding over 1 rounds. Their latest funding round was raised on Aug 26, 2021 in the amount of $390K.

  • $1M$10M

    TumorGen, Inc.'s revenue is estimated to be in the range of $1M$10M

Company Leadership

  • Stylized image of a person
    S. R.
    Coo
    Phone icon
    Mobile Phone

Employee Directory

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust LeadIQ to help them build pipeline confidently.

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.